| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 1,445 | 1,004 | 1,107 | 394 | 735 |
| Sales Growth | +43.92% | -9.30% | +180.96% | -46.39% | +200.00% |
| Net Income | -2,643 | -3,094 | -2,385 | -1,611 | -4,491 |
| Net Income Growth | +14.58% | -29.73% | -48.04% | +64.13% | +46.07% |
Netscientific Plc (NSCI.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NetScientific PLC is a transatlantic healthcare technology company. The group is focused on sourcing, funding, and commercializing technologies and companies that have the potential to treat chronic diseases and significantly improve the health and well-being of people. Its portfolio consists of WANDA Health, an analytics company that uses machine learning to derive a personalized risk score for Congestive Heart Failure patients, a provider of a non-invasive glucose monitoring wearable device, Vortex Biosciences which is engaged in circulating tumor cell identification, selection, and analysis for disease monitoring and personalized therapeutic prescribing, and Glycotest which provides non-invasive blood tests for liver cancers and fibrosis-cirrhosis.